S-1

“S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an...” NCT04267549 ↗

“Tegafur Gimeracil Oteracil Potassium Capsule is a novel oral derivative of the 5-fluorouracil(5-FU) prodrug tegafur combined with two modulators. Recent clinical trial has...” NCT01492543 ↗

“In this open-label, single-arm, phase 2 trial, in each 21-day cycle, eligible patients received 200 mg intravenous camrelizumab in the first day, 500 mg oral apatinib once...” PMID 35304622 ↗ Mar 2022

“SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25...” NCT06121700 ↗

“Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or...” NCT01781520 ↗

“Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine...” NCT03680261 ↗

“A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin...” PMID 32583567 ↗ Jun 2020

“Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid...” NCT02870153 ↗

“Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130...” NCT05975749 ↗

“SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid,...” NCT02356276 ↗

“S-1 is orally administer by BSA (\<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses a day after breakfast and dinner for 14 days every three weeks...” NCT03961867 ↗

“The control group includes three treatment regimens: AG, nal-IRI + 5-FU/LV, and S-1. If participants are randomized to the control group, they will receive the treatment which...” NCT07262567 ↗

“The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg...” NCT04782791 ↗

“Adjuvant chemotherapy was administered as either tegafur-gimeracil-oteracil (S-1) at an initial dose of 40 mg/m2 per dose orally twice per day for 28 consecutive days, followed...” PMID 38906161 ↗ Jun 2024

“Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on...” NCT02193594 ↗

“S-1 (administered orally twice daily on days 1-14 of each 21-day cycle, with the daily dose determined by body surface area: \<1.25 m², 80 mg/day; ≥1.25 to \<1.5 m², 100...” NCT07658872 ↗

“SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid...” NCT03788226 ↗

“The SOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral S-1 (tegafur/gimeracil/oteracil) 40-60 mg twice daily, taken on days 1-14 followed by 7 days off, in a...” NCT07007182 ↗

“The SOX regimen consisted of three cycles of oxaliplatin 130 mg/m2 intravenous on day 1 and oral Tegafur/Gimeracil/Oteracil (S-1) 80 mg/m2 twice daily on days 1-14, repeated...” PMID 41181842 ↗ Oct 2025

“Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled...” PMID 30940189 ↗ Apr 2019

“Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or...” NCT03398291 ↗

“S-1 (Teysuno®) is an oral fluoropyrimidine that has shown comparable efficacy to 5FU and capecitabine in gastrointestinal cancers but is associated with a much lower incidence of HFS.” NCT01918852 ↗

“The HIPEC group was treated with cisplatin (60 mg/m2) administered with a HIPEC device on days 1 and 3 (30 mg/m2 each time), along with oral S-1, 40-60 mg, twice daily, for 14 days.” PMID 35100917 ↗ 2022

“Investigators previously developed oral fluoropyrimidine-based triplet regimen (oxaliplatin, irinotecan and S-1) and investigated in 32 patients with advanced biliary tract cancer.” NCT04662112 ↗

“Monotherapy with S-1, oral fluoropyrimidine, shows non-inferiority to gemcitabine in overall survival (OS) with good tolerability for advanced pancreatic cancer in Asian patients.” NCT02945267 ↗

“Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w” NCT06685887 ↗

“S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.” NCT05138159 ↗

“A Phase I Study of Concurrent Radiotherapy and Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.” NCT02277158 ↗

“Iparomlimab and Tuvonralimab:5 mg/kg Q3W lenvatinib:8 mg/day orally SOX：oxaliplatin (130 mg/m² Q3W intravenous infusion), and S-1 (40 mg/m² BID orally on days 1-14)” NCT07151209 ↗

“S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2)” NCT05497739 ↗

“The standard treatment for elderly patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy with S-1.” PMID 40001034 ↗ Feb 2025

“A combination of Fruquintinib and Candonilimab (AK104) and s-1 for advanced or metastatic esophageal squamous cell carcinoma could be a novel therapy.” NCT06487702 ↗

“S-1 is a new oral fluoropyrimidine derivative in which tegafur is combined with two 5-chloro-2, 4-dihydroxypyridine modulators and oteracil potassium” NCT03403101 ↗

“Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)” NCT06192186 ↗

“S-1 (Tegafur, Gimeracil, Oteracil): Administered orally twice daily (after breakfast and dinner) on Days 1-14, followed by a 7-day rest period.” NCT07315854 ↗

“oral S-1 (tegafur 40-60 mg, gimeracil and oteracil potassium in fixed 1:0.4:1 molar ratio) taken twice daily on days 1-14 of a 21-day cycle” NCT07315035 ↗

“S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.)” NCT06576921 ↗

“S-1 capsule is an novel oral anticancer drug that combines tegafur, a prodrug of 5-fluorouracil, with gimeracil and oteracil potassium.” NCT02223611 ↗

“Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles” NCT04136600 ↗

“S-1 is an oral 5-fluorouracil (5-FU) prodrug, and shown to be non-inferior to gemcitabine on OS for unresectable pancreatic cancer.” NCT03636308 ↗

“SOX chemotherapy consists of S-1 in combination with oxaliplatin and is administered as part of postoperative adjuvant treatment” NCT07507916 ↗

“All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56.” NCT04380480 ↗

“oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle)” NCT07182565 ↗

“Phase II Study of Neoadjuvant Adebrelimab, Docetaxel, Oxaliplatin, and S-1 in Patients With Resectable Advanced Gastric Cancer” NCT06475417 ↗

“S-1 (Tegafur, Gimeracil, and Oteracil Potassium): 40-60 mg (based on Body Surface Area), oral, twice daily on Days 1-14.” NCT07353684 ↗

“SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)” NCT05602935 ↗

“S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)” NCT06925243 ↗

“Tegafur-gimeracil-oteracil (S-1): 80-120mg per day, taken twice a day, from day 1 to day 14, and from day 21 onwards.” NCT07386704 ↗

“Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year.” NCT06354140 ↗

“Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg” NCT02725424 ↗

“S-1 is an oral anti-cancer agent composed of tegafur, 5-chloro-2,4-dihydroxypyridine, and oteracil potassium.” NCT02442362 ↗

“S-1: 40-60 mg/m², oral administration (p.o.), twice daily (b.i.d.), on Days 1 to 14; repeated every 21 days.” NCT07474324 ↗

“Adjuvant chemotherapy with either the XELOX (capecitabine + oxaliplatin) or SOX (S-1 + oxaliplatin) regimen” NCT07098949 ↗

“Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab” NCT06405113 ↗

“Patients receive perioperative treatment with S-1 plus oxaliplatin (SOX) in combination with Serplulimab.” NCT07699939 ↗

“S-1: 40 mg/m², oral administration (p.o.), twice daily (b.i.d.), on Days 1 to 14; repeated every 21 days.” NCT07263386 ↗

“with intraperitoneal paclitaxel and cisplatin, and oral S-1 in gastric cancer with peritoneal metastasis.” NCT02995850 ↗

“Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14.” NCT04609176 ↗

“Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.” NCT06422156 ↗

“Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks.” NCT05028439 ↗

“40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days” NCT02512380 ↗

“S-1 PO BID Days 1-14 (dose based on BSA: \<1.25 m² = 40 mg, 1.25-\<1.5 m² = 50 mg, ≥1.5 m² = 60 mg)” NCT07053150 ↗

“Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).” NCT07000253 ↗

“S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.” NCT05586061 ↗

“SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.” NCT03413514 ↗

“and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)” NCT03691454 ↗

“S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers.” PMID 29506478 ↗ Mar 2018

“S-1 : 40-60 mg/dose, orally, twice daily (bid), daily (days 1-14) , every 3 weeks (q3w).” NCT07602140 ↗

“Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w” NCT05193292 ↗

“Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases” NCT02949258 ↗

“Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.” NCT04792515 ↗

“SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.” NCT05322577 ↗

“Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin” NCT02867397 ↗

“S-1 administered orally for 14 consecutive days followed by a 7-day rest period.” NCT07072351 ↗

“Adjuvant chemotherapy consisted of six to eight cycles of S-1 plus oxaliplatin.” PMID 29743043 ↗ May 2018

“S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)” NCT03589950 ↗

“Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.” NCT06410651 ↗

“Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.” NCT06429839 ↗

“S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles.” NCT05648487 ↗

“Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)” NCT06730009 ↗

“S-1 was calculated according to body surface area , P.O., bid, d1-d14.” NCT05524974 ↗

“Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1” NCT07689539 ↗

“Drug: S-1: S-1 will be administered at 40 mg/m2 orally, twice daily” NCT01406249 ↗

“orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14” NCT04483076 ↗

“S-1 or Capecitabine or Eriblin (previously treated with taxane)” NCT06135714 ↗

“oral S-1 [tegafur-gimeracil-oteracil potassium] + oxaliplatin” PMID 39162872 ↗ Aug 2024

“Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W” NCT06662877 ↗

“gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel” NCT05268692 ↗

“S-1 (35 mg/m2) is given twice daily per oral on day 1 to 7.” NCT06903273 ↗

“S-1 is a new generation of oral fluorouracil derivatives” NCT03585062 ↗

“Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)” NCT06123455 ↗

“Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w” NCT07026149 ↗

“S-1: Orally, within 30 minutes after ingestion of food.” NCT01283217 ↗

“patients take oral S-1 twice daily from Day 1 to Day 14” NCT07504471 ↗

“Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle” NCT03654612 ↗

“S-1 80mg/m2/day, orally intake on radiotherapy days.” NCT03427684 ↗

“fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)” NCT05177068 ↗

“oral administration of S-1 at 40-60 mg twice a day” NCT07033143 ↗

“Induction chemotherapy -- S-1 35mg/m2 bid day 1-14” NCT02495493 ↗

“S-1 ((Tegafur, Gimeracil, and Oteracil Potassium)” NCT02504229 ↗

“S-1 orally intake as perioperative chemotherapy” NCT05970627 ↗

“or S-1: 40-60mg according to BSA, bid, D1-14” NCT06888037 ↗

“S-1 orally, 400 mg/d, bid on Day 1-21, Q28d” NCT02981641 ↗

“days 1-14: oral S-1 80 mg/m², 2 times/Day.” NCT06459921 ↗

“S-1 40mg/m2 po bid d1-14, every 21 days” NCT06564298 ↗

“S-1: 40 mg/m² taken orally twice daily.” NCT06468280 ↗

“adjuvant systemic chemotherapy with S-1” NCT02205008 ↗

“Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w” NCT04744649 ↗

“SOX: S-1: 40 mg/m², oral, bid, d1-14” NCT07621562 ↗

“S-1 40 mg/m2，po, bid，d1\~d14，q3w” NCT05101616 ↗

“S-1, 40-60mg,PO, Bid, d1-14，Q3W” NCT07325630 ↗

“oral chemotherapy:S-1: 80mg/m2” NCT04889768 ↗

“S-1: 40-60 mg Bid, d1-14, q3w” NCT06266871 ↗

“S-1: 40-60mg bid, D1-14, Q3W” NCT05024812 ↗

“oxaliplatin plus S-1 capsule” NCT02960061 ↗

“S-1 40-60mg bid, d1-d14,Q3w” NCT04631757 ↗

“S-1 40-60mg p.o. bid d1-14” NCT03279614 ↗

“S-1 40 mg/m2 bid d1-14 po” NCT02163291 ↗

“SOX (oxaliplatin + S-1)” NCT05739045 ↗

“S-1 40-60mg Bid, Oral” NCT02648841 ↗

“SOX: S-1：40 mg” NCT07607210 ↗

NCT01946061 ↗

NCT06789679 ↗

NCT01849380 ↗

NCT04781413 ↗

NCT04781686 ↗

NCT04027764 ↗

NCT00677144 ↗

NCT06171321 ↗

NCT03061058 ↗

NCT01128998 ↗

NCT02182778 ↗

NCT01997957 ↗

NCT07374250 ↗

NCT06571461 ↗

NCT02779608 ↗

NCT05529355 ↗

NCT04886193 ↗

NCT01747707 ↗

NCT00152217 ↗

NCT06213519 ↗

NCT05853172 ↗

NCT05867121 ↗

NCT04566380 ↗

NCT04152889 ↗

NCT06584227 ↗

NCT01180153 ↗

NCT03607656 ↗

NCT07194005 ↗

NCT00514163 ↗

NCT06510010 ↗

NCT07366528 ↗

NCT03276156 ↗

NCT07556640 ↗

NCT06048913 ↗

NCT01430052 ↗

NCT00869635 ↗

NCT03726021 ↗

NCT03517618 ↗

NCT02817425 ↗

NCT05948449 ↗

NCT02979691 ↗

NCT00524706 ↗

NCT03941561 ↗

NCT07070479 ↗

NCT05774964 ↗

NCT00580359 ↗

NCT06519591 ↗

NCT05771480 ↗

NCT02878889 ↗

NCT01608646 ↗

NCT00805012 ↗

NCT06766578 ↗

NCT01291615 ↗

NCT02124317 ↗

NCT00503321 ↗

NCT05138159 ↗

NCT07243938 ↗

NCT05528367 ↗

NCT03885219 ↗

NCT01534546 ↗

NCT06187597 ↗

NCT07018063 ↗

NCT01671449 ↗

NCT07356466 ↗

NCT00209638 ↗

NCT02606916 ↗

NCT06427005 ↗

NCT07515625 ↗

NCT06901622 ↗

NCT02216149 ↗

NCT07561775 ↗

NCT05026905 ↗

NCT01291407 ↗

NCT03777462 ↗

NCT02634502 ↗

NCT05687357 ↗

NCT03457337 ↗

NCT01533324 ↗

NCT06229496 ↗

NCT03380689 ↗

NCT05237349 ↗

NCT00479076 ↗

NCT01110941 ↗

NCT03615326 ↗

NCT00602745 ↗

NCT01645748 ↗

NCT03443492 ↗

NCT02129322 ↗

NCT01811277 ↗

NCT00506207 ↗

NCT06169410 ↗

NCT02191566 ↗

NCT00525005 ↗

NCT03718624 ↗

NCT02128243 ↗

NCT00429858 ↗

NCT00891332 ↗

NCT02114359 ↗

NCT00527930 ↗

NCT00202969 ↗

NCT05144854 ↗

NCT01375972 ↗

NCT04808687 ↗

NCT05403242 ↗

NCT02592538 ↗

NCT00587145 ↗

NCT03950141 ↗

NCT02131493 ↗

NCT00506571 ↗

NCT05052931 ↗

NCT07621484 ↗

NCT01227239 ↗

NCT03815461 ↗

NCT02539225 ↗

NCT01175460 ↗

NCT04694183 ↗

NCT02280070 ↗

NCT06732856 ↗

NCT01175447 ↗

NCT04694404 ↗

NCT03278015 ↗

NCT03986294 ↗

NCT02813967 ↗

NCT02525237 ↗

NCT03210064 ↗

NCT05627414 ↗

NCT00553696 ↗

NCT05720559 ↗

NCT00072787 ↗

NCT06598917 ↗

NCT03271073 ↗

NCT00209677 ↗

NCT07304258 ↗

NCT03263741 ↗

NCT04047953 ↗

NCT07522151 ↗

NCT06447636 ↗

NCT01756183 ↗

NCT02716688 ↗

NCT07636824 ↗

NCT00569790 ↗

NCT00569699 ↗

NCT00209664 ↗

NCT00398424 ↗

NCT01193452 ↗

NCT06914687 ↗

NCT02291211 ↗

NCT00770874 ↗

NCT02423278 ↗

NCT04128800 ↗

NCT02943252 ↗

NCT01074996 ↗

NCT03977220 ↗

NCT02301481 ↗

NCT02564367 ↗

NCT01980810 ↗

NCT00398307 ↗

NCT04258644 ↗

NCT01459185 ↗

NCT07685704 ↗

NCT01795027 ↗

NCT06038461 ↗

NCT00569335 ↗

NCT02347904 ↗

NCT05519202 ↗

NCT04195828 ↗

NCT04258657 ↗

NCT00515190 ↗

NCT03660449 ↗

NCT07492615 ↗

NCT00816543 ↗

NCT03397199 ↗

NCT05872685 ↗

NCT05773092 ↗

NCT06451211 ↗

NCT00915382 ↗

NCT02945267 ↗

NCT07038629 ↗

NCT02425137 ↗

NCT03830606 ↗

NCT03779464 ↗

NCT03843853 ↗

NCT04890392 ↗

NCT03320629 ↗

NCT06256328 ↗

NCT01364376 ↗

NCT06166589 ↗

NCT00652054 ↗

NCT03585062 ↗

NCT06046963 ↗

NCT07483567 ↗

NCT06693128 ↗

NCT02146703 ↗

NCT03708536 ↗

NCT02947061 ↗

NCT03162510 ↗

NCT01415713 ↗

NCT01284413 ↗

NCT04221555 ↗

NCT02459652 ↗

NCT02867839 ↗

NCT03801668 ↗

NCT05636150 ↗

NCT01980407 ↗

NCT06454435 ↗

NCT06385873 ↗

NCT03850769 ↗

NCT06657690 ↗

NCT05111444 ↗

NCT02862535 ↗

NCT03129256 ↗

NCT05822453 ↗

NCT02688023 ↗

NCT01815307 ↗

NCT06746545 ↗

NCT00142350 ↗

NCT01426646 ↗

NCT03662035 ↗

NCT01929421 ↗

NCT04062058 ↗

NCT06194734 ↗

NCT02322593 ↗

NCT06730373 ↗

NCT02527785 ↗

NCT05699655 ↗

NCT01610479 ↗

NCT00400179 ↗

NCT03051373 ↗

NCT03991104 ↗

NCT01679340 ↗

NCT01583361 ↗

NCT06487429 ↗

NCT06532617 ↗

NCT02527824 ↗

NCT01286766 ↗

NCT05729646 ↗

NCT07384234 ↗

NCT00400023 ↗

NCT04338438 ↗

NCT05218148 ↗

NCT06779318 ↗

NCT00960349 ↗

NCT00651742 ↗

NCT03007446 ↗

NCT01824459 ↗

NCT04217096 ↗

NCT06487715 ↗

NCT05218889 ↗

NCT00980603 ↗

NCT04319471 ↗

NCT04070313 ↗

NCT02317471 ↗

NCT03668366 ↗

NCT05204173 ↗

NCT00438100 ↗

NCT04274270 ↗

NCT04863430 ↗

NCT02618356 ↗

NCT04999332 ↗

NCT05170542 ↗

NCT00639327 ↗

NCT03990103 ↗

NCT00287755 ↗

NCT00287768 ↗

NCT01704690 ↗

NCT00961077 ↗

NCT03878472 ↗

NCT01515748 ↗

NCT04101929 ↗

NCT02855125 ↗

NCT03701373 ↗

NCT05593458 ↗

NCT03475615 ↗

NCT01824004 ↗

NCT03823118 ↗

NCT01963325 ↗

NCT07569068 ↗

NCT03415802 ↗

NCT03636308 ↗

NCT01198392 ↗

NCT03700333 ↗

NCT07464756 ↗

NCT04989985 ↗

NCT00721916 ↗

NCT02229058 ↗

NCT02529878 ↗

NCT01285557 ↗

NCT01718626 ↗

NCT02677597 ↗

NCT02090153 ↗

NCT01403259 ↗

NCT05769725 ↗

NCT02296658 ↗

NCT06490107 ↗

NCT01831531 ↗

NCT01388790 ↗

NCT02387138 ↗

NCT00343668 ↗

NCT06341595 ↗

NCT00278863 ↗

NCT01821248 ↗

NCT01693445 ↗

NCT02736552 ↗

NCT01693432 ↗

NCT01693419 ↗

NCT03137004 ↗

NCT06109779 ↗

NCT05441254 ↗

NCT05410847 ↗

NCT03769935 ↗

NCT01854749 ↗

NCT06555471 ↗

NCT02631460 ↗

NCT03825328 ↗

NCT00980382 ↗

NCT03428425 ↗

NCT01946646 ↗

NCT02338518 ↗

NCT01096745 ↗

NCT06939452 ↗

NCT02734680 ↗

NCT01106066 ↗

NCT03946969 ↗

NCT00677443 ↗

NCT04982939 ↗

NCT01783951 ↗

NCT01090505 ↗

NCT00651833 ↗

NCT07025889 ↗

NCT02623153 ↗

NCT03567629 ↗

NCT04208347 ↗

NCT04207918 ↗

NCT05184803 ↗

NCT05048524 ↗

NCT01552980 ↗

NCT01713387 ↗

NCT02370849 ↗

NCT06664021 ↗

NCT02359058 ↗

NCT00652561 ↗

NCT06881017 ↗

NCT05424692 ↗

“Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of...” NCT05594381 ↗

“adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance...” NCT06739252 ↗

“After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX)” NCT06761846 ↗

“and tegafur, with the dose of tegafur determined based on body surface area and administered orally twice daily for 14 days every 3 weeks” NCT06939439 ↗

“S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)” NCT02454062 ↗

“S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU);” NCT00197431 ↗

“oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid” NCT04198051 ↗

“UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules)” NCT00439517 ↗

“Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)” NCT07092449 ↗

“Tegafur: 40-60 mg/m² twice daily (d1-14) every 3 weeks for 2 cycles” NCT07530549 ↗

“Tegafur (40 mg/m2, p.o., Bid, Q3W, for day 1 to day 14 per cycle)” NCT06196697 ↗

“Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time” NCT05050760 ↗

“DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles” NCT03154983 ↗

“Tegafur: 40-60mg, BID, po, d1-d10, repeat every 15 days” NCT06361316 ↗

“Tegafur (Gimeracil and Oteracil Potassium Capsules)” NCT05170503 ↗

“TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)” NCT02817425 ↗

“Tegafur,Gimeracil and Oteracil Porassium Capsules” NCT06992362 ↗

“Tegafur: 80mg/m2 Q3W on day 1-14 of each cycle” NCT07453875 ↗

“Tegafur 40\~60mg b.i.d. p.o. D1\~D14” NCT06283121 ↗

“Drug: Tegafur” NCT06988956 ↗

“Tegafur” NCT04135781 ↗

NCT06603974 ↗

NCT05498766 ↗

NCT05955157 ↗

NCT03448549 ↗

NCT06439550 ↗

NCT06354140 ↗

NCT05817201 ↗

NCT05070598 ↗

NCT04571489 ↗

NCT06383078 ↗

NCT05451290 ↗

NCT03175705 ↗

NCT02749526 ↗

NCT03175679 ↗

NCT03204032 ↗

NCT03204019 ↗

NCT04415853 ↗

NCT03406299 ↗

NCT04216758 ↗

NCT06461910 ↗

NCT03702491 ↗

NCT06396585 ↗

NCT07165847 ↗

NCT05914610 ↗

NCT05223088 ↗

NCT06525714 ↗

NCT05325528 ↗

NCT00378716 ↗

NCT00207831 ↗

NCT06339619 ↗

“postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium +...” NCT06238167 ↗

“Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗

“Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily” NCT05468138 ↗

“Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral” NCT04677673 ↗

“S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy in these subsets of ESCC patients” PMID 35449578 ↗ Apr 2022

“Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area）” NCT05122091 ↗

“A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium” NCT07023315 ↗

“Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)” NCT04384601 ↗

“Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral” NCT04410887 ↗

“Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.” NCT04799548 ↗

“Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)” NCT00503321 ↗

“Tegafur Gimeracil Oteracil Potassium Capsules (S-1)” NCT07304258 ↗

NCT03316326 ↗

NCT00985556 ↗

NCT00134095 ↗

NCT00974389 ↗

NCT00660894 ↗

NCT04515615 ↗

NCT03096184 ↗

NCT01492543 ↗

NCT00687843 ↗

NCT03013010 ↗

NCT02746796 ↗

NCT03267121 ↗

NCT03006705 ↗

NCT00625937 ↗

NCT05095467 ↗

NCT06422858 ↗

NCT00336947 ↗

NCT00216034 ↗

NCT03002831 ↗

NCT00994968 ↗

NCT05960955 ↗

NCT00659113 ↗

NCT04997837 ↗

NCT00182611 ↗

NCT00088816 ↗

“oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle)” NCT07182565 ↗

“Tegafur-gimeracil-oteracil (S-1): 80-120mg per day, taken twice a day, from day 1 to day 14, and from day 21 onwards.” NCT07386704 ↗

“Drug: Tegafur-Gimeracil-Oteracil” NCT05813015 ↗

NCT03904225 ↗

NCT05161572 ↗

NCT06255379 ↗

NCT06662877 ↗

NCT04377048 ↗

NCT02867397 ↗

NCT01918852 ↗

NCT05396326 ↗

NCT01845337 ↗

NCT05346874 ↗

NCT06158919 ↗

“Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.” PMID 19052037 ↗ Dec 2008

“Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care” NCT05955157 ↗

“Followed by TS-1 based chemoradiation.” NCT02754180 ↗

“S-1 (TS-1) and Oxaliplatin (Oxalitin)” NCT00961077 ↗

“Gemcitabine;gemzer , S-1;TS-1” NCT01713387 ↗

“TS-1 80mg/m2/day (PO)” NCT01283204 ↗

“TS-1 (S-1)” NCT00152217 ↗

NCT01269255 ↗

NCT00150670 ↗

NCT01100801 ↗

NCT00498225 ↗

NCT03519074 ↗

NCT00209651 ↗

NCT01171755 ↗

NCT00209729 ↗

NCT03382600 ↗

NCT01761461 ↗

NCT03814759 ↗

NCT00316745 ↗

NCT05065957 ↗

NCT03559348 ↗

NCT00252161 ↗

NCT03252808 ↗

NCT00436423 ↗

NCT01874678 ↗

NCT01269216 ↗

NCT00512681 ↗

NCT00195572 ↗

NCT00284258 ↗

NCT00874328 ↗

NCT04172402 ↗

NCT01131689 ↗

NCT00531245 ↗